North America Wound Debridement Products Market, By Product Type (Hydrosurgical Debridement Devices, Low Frequency Ultrasound Devices, Surgical Wound Debridement Devices, Mechanical Debridement Pads, Traditional Wound Debridement Devices, Larval Therapy), By Application (Chronic Ulcers, Surgical Wounds, Traumatic Wounds, Burn Cases), End User (Hospital, Ambulatory Surgical Centers, Specialized Clinics, Nursing Facilities, Others), and By Country (U.S., Canada)-

Published In : Jun 2023

Code : CMI3665

Pages :152

Formats :

Excel and PDF

Industry : Medical Devices

Market News

North America Wound Debridement Products Market: Key Developments

On November 5, 2020, Sanara Medtech, a U.S. based Biotechnology Company, launched Biakos, antimicrobial wound gel. It is hydrogel wound dressing that can be used with another product Biakos skin and wound cleanser to enhance effectiveness. Cleanser can clean wound and disrupt biofilm of microbes. It can remain on the wound for 72 hours. It can be used for diabetic foot ulcers, post-surgical wounds, pressure ulcers, first and second-degree burns, grafts and donor sites.

On April 8, 2021, Healogics LLC, a U.S.-based advanced wound care provider, launched healing awareness program on foot health called ‘The Healogics Foot Health campaign’ to prevent chronic wounds. In this program, people were made aware regarding need for regular foot screening to detect non-healing wounds. The team reached out to healthcare providers to encourage foot screening and provide patient focused educational resources. The program is dedicated to empowering both patients and healthcare providers with resources to help improve health, heal wounds and prevent amputations.

On March 8, 2023, Ceapro Inc., a Canada-based biotechnology company, announced that its study in collaboration with The Angiogenesis Foundation on Avena Sativa derived therapeutics β-Glucan and Avenanthramide was accepted for presentation at annual meeting of wound healing society. It was found that oats (Avena Sativa) can accelerate wound healing in mice by anti-inflammatory mechanisms and reduce scar formation. It can stimulate angiogenesis.

On January 1, 2022, Scapa Healthcare, a U.S.-based wound dressing company signed exclusive technology licensing agreement with Synedgen Inc., a U.S. based medical technology company for novel wound care technology. Under the terms of the agreement, Scapa Healthcare has exclusive rights over Synedgen’s glycopolymer technology in the field of dermal wounds and surgical care applications both over the counter and in the professional setting.